Both bisphosphonate-naive patients in the cohort developed symptomatic hypophosphatemia and hypocalcemia requiring oral supplementation. Acute adverse events associated with zoledronic acid infusions ...

Pharmaceutical agents targeting distinct therapeutic pathways can differently influence bone metabolism, notably exemplified by nitrogen-containing bisphosphonates and glucocorticoids. Objective This ...

The median total clinic time was not significantly shorter for patients who received subcutaneous trastuzumab/pertuzumab than for those who received the intravenous ...

Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...

In general, IV bisphosphonates are very well tolerated, and patients rarely require dose modification. In the comparative phase 3 trial of zoledronic acid and pamidronate in patients with breast ...

Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy and for the treatment of multiple myeloma and bone metastases of solid tumors, in conjunction with standard ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

Zoledronic acid treatment was associated with reduced fracture rates among pediatric patients with primary and secondary skeletal fragility. Treatment with zoledronic acid is associated with reduced ...

Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...